Objective:This study aims to evaluate the clinical efficacy of non-invasive positive pressure ventilation(NIPPV)in patients with severe bronchial asthma combined with respiratory failure.Methods:90 patients with sever...Objective:This study aims to evaluate the clinical efficacy of non-invasive positive pressure ventilation(NIPPV)in patients with severe bronchial asthma combined with respiratory failure.Methods:90 patients with severe bronchial asthma combined with respiratory failure between September 2022 and December 2023 were selected for the study and randomly divided into the experimental group(NIPPV-assisted treatment)and the control group.The differences between the two groups were compared in terms of total effective rate of treatment,days of clinical symptom disappearance,days of hospitalization,lung function indexes,incidence of adverse reactions,and quality of life.Results:Patients in the experimental group had a significantly higher total effective rate of treatment(97.78%)than the control group(75.56%).In terms of pulmonary function indexes,patients in the experimental group showed significant improvement after treatment,especially the increase in forced expiratory volume and forced vital capacity,while these improvements were not as obvious in the control group.In addition,the incidence of adverse reactions was significantly lower in the experimental group than in the control group,suggesting that the application of NIPPV is relatively safe.Quality of life assessment also showed that patients in the experimental group had significantly better quality of life than the control group after treatment.Conclusion:This study demonstrated the effectiveness of NIPPV as an adjunctive treatment for severe bronchial asthma combined with respiratory failure.NIPPV can improve lung function,reduce the incidence of adverse effects,increase the overall effectiveness of the treatment,and contribute to the improvement of patients'quality of life.Therefore,NIPPV should be regarded as an effective and safe treatment in clinical management,especially in patients with severe bronchial asthma combined with respiratory failure,where its application has potential clinical significance.展开更多
A 53-year-old man with a history of blood transfusion at the age of 20 was admitted to our hospital because of liver dysfunction. He had bronchial asthma when he was 18 years old, which naturally resolved within 2 yea...A 53-year-old man with a history of blood transfusion at the age of 20 was admitted to our hospital because of liver dysfunction. He had bronchial asthma when he was 18 years old, which naturally resolved within 2 years. However, his bronchial asthma recurred at the age of 45 and was treated with oral theophylline. He was diagnosed as having chronic hepatitis C based on the histological and clinical findings, and then interferon (IFN) therapy was administered. The frequency of bronchial asthma attack was gradually decreasing after IFN therapy with marked improvement of hypereosinophilia. He achieved sustained viral response (SVR) and his bronchial asthma did not worsen even after the cessation of IFN. Hepatitis C virus (HCV) infection and IFN therapy were considered in the remission of asthma in this case. HCV infection could be the cause of bronchial asthma, especially in patients with late appearance of asthma.展开更多
【目的】基于网状Meta分析评价中成药联合吸入疗法对儿童支气管哮喘的疗效及安全性。【方法】计算机检索中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、万方医学数据库(Wanfang Data)、维普信息资源系统(VIP)、Embase、PubMe...【目的】基于网状Meta分析评价中成药联合吸入疗法对儿童支气管哮喘的疗效及安全性。【方法】计算机检索中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、万方医学数据库(Wanfang Data)、维普信息资源系统(VIP)、Embase、PubMed、Web of Science等数据库中收录的中成药联合吸入疗法治疗儿童支气管哮喘的临床随机对照试验,应用Stata14对数据进行网状Meta分析。【结果】最终纳入28项研究,包括7种中成药,分别为寒喘祖帕颗粒、槐杞黄颗粒、痰热清注射液、小儿肺热咳喘颗粒、喘可治注射液、玉屏风颗粒、珠贝定喘丸。网状Meta分析结果显示,在提高总有效率方面,优选概率排名曲线(surface under the cumulative ranking curve,SUCRA)的概率排序居前3位的依次为痰热清注射液联合吸入疗法、喘可治注射液联合吸入疗法、珠贝定喘丸联合吸入疗法;改善肺功能指标呼气峰值流速(peak expiratory flow,PEF)、第1秒用力呼气容积(forced expiratory volume at one second,FEV1)、FEV1与用力肺活量(forced vital capacity,FVC)的比值(FEV1/FVC)最优的干预措施分别为痰热清注射液联合吸入疗法、寒喘祖帕颗粒联合吸入疗法、珠贝定喘丸联合吸入疗法;对不良反应发生率的SUCRA概率排序的分析结果显示,小儿肺热咳喘颗粒联合吸入疗法可能为副作用最小的干预措施,珠贝定喘丸联合吸入疗法可能为副作用较大的干预措施。【结论】中成药联合吸入疗法较单纯吸入疗法可提高小儿支气管哮喘的有效率及改善肺功能指标,且安全性较好。展开更多
文摘Objective:This study aims to evaluate the clinical efficacy of non-invasive positive pressure ventilation(NIPPV)in patients with severe bronchial asthma combined with respiratory failure.Methods:90 patients with severe bronchial asthma combined with respiratory failure between September 2022 and December 2023 were selected for the study and randomly divided into the experimental group(NIPPV-assisted treatment)and the control group.The differences between the two groups were compared in terms of total effective rate of treatment,days of clinical symptom disappearance,days of hospitalization,lung function indexes,incidence of adverse reactions,and quality of life.Results:Patients in the experimental group had a significantly higher total effective rate of treatment(97.78%)than the control group(75.56%).In terms of pulmonary function indexes,patients in the experimental group showed significant improvement after treatment,especially the increase in forced expiratory volume and forced vital capacity,while these improvements were not as obvious in the control group.In addition,the incidence of adverse reactions was significantly lower in the experimental group than in the control group,suggesting that the application of NIPPV is relatively safe.Quality of life assessment also showed that patients in the experimental group had significantly better quality of life than the control group after treatment.Conclusion:This study demonstrated the effectiveness of NIPPV as an adjunctive treatment for severe bronchial asthma combined with respiratory failure.NIPPV can improve lung function,reduce the incidence of adverse effects,increase the overall effectiveness of the treatment,and contribute to the improvement of patients'quality of life.Therefore,NIPPV should be regarded as an effective and safe treatment in clinical management,especially in patients with severe bronchial asthma combined with respiratory failure,where its application has potential clinical significance.
文摘A 53-year-old man with a history of blood transfusion at the age of 20 was admitted to our hospital because of liver dysfunction. He had bronchial asthma when he was 18 years old, which naturally resolved within 2 years. However, his bronchial asthma recurred at the age of 45 and was treated with oral theophylline. He was diagnosed as having chronic hepatitis C based on the histological and clinical findings, and then interferon (IFN) therapy was administered. The frequency of bronchial asthma attack was gradually decreasing after IFN therapy with marked improvement of hypereosinophilia. He achieved sustained viral response (SVR) and his bronchial asthma did not worsen even after the cessation of IFN. Hepatitis C virus (HCV) infection and IFN therapy were considered in the remission of asthma in this case. HCV infection could be the cause of bronchial asthma, especially in patients with late appearance of asthma.
文摘【目的】基于网状Meta分析评价中成药联合吸入疗法对儿童支气管哮喘的疗效及安全性。【方法】计算机检索中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、万方医学数据库(Wanfang Data)、维普信息资源系统(VIP)、Embase、PubMed、Web of Science等数据库中收录的中成药联合吸入疗法治疗儿童支气管哮喘的临床随机对照试验,应用Stata14对数据进行网状Meta分析。【结果】最终纳入28项研究,包括7种中成药,分别为寒喘祖帕颗粒、槐杞黄颗粒、痰热清注射液、小儿肺热咳喘颗粒、喘可治注射液、玉屏风颗粒、珠贝定喘丸。网状Meta分析结果显示,在提高总有效率方面,优选概率排名曲线(surface under the cumulative ranking curve,SUCRA)的概率排序居前3位的依次为痰热清注射液联合吸入疗法、喘可治注射液联合吸入疗法、珠贝定喘丸联合吸入疗法;改善肺功能指标呼气峰值流速(peak expiratory flow,PEF)、第1秒用力呼气容积(forced expiratory volume at one second,FEV1)、FEV1与用力肺活量(forced vital capacity,FVC)的比值(FEV1/FVC)最优的干预措施分别为痰热清注射液联合吸入疗法、寒喘祖帕颗粒联合吸入疗法、珠贝定喘丸联合吸入疗法;对不良反应发生率的SUCRA概率排序的分析结果显示,小儿肺热咳喘颗粒联合吸入疗法可能为副作用最小的干预措施,珠贝定喘丸联合吸入疗法可能为副作用较大的干预措施。【结论】中成药联合吸入疗法较单纯吸入疗法可提高小儿支气管哮喘的有效率及改善肺功能指标,且安全性较好。
